COLL Fair Value Estimate
$106.16214.3% undervalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Collegium Pharmaceutical Inc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts.
Current Price
$33.78
-3.01%GoodMoat Value
$106.16
214.3% undervaluedProfile
Valuation (TTM)
Market Cap$1.07B
P/E14.31
EV—
P/B3.56
Shares Out31.75M
P/Sales1.35
Revenue$796.33M
EV/EBITDA7.60
Collegium Pharmaceutical Inc (COLL) Valuation
COLL Valuation Metrics
FCF$327.58M
FCF Growth Rate50.00%
EPS Growth (CAGR)18.64%
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →COLL Valuation & Fair Value Analysis
Collegium Pharmaceutical Inc (COLL) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Collegium Pharmaceutical Inc is $106.16. The current stock price is $33.78, suggesting the stock is 214.3% undervalued.
The price-to-earnings (P/E) ratio is 14.31. Price-to-book ratio is 3.56. Price-to-sales ratio is 1.35. Enterprise value to EBITDA is 7.60. PEG ratio is 0.03.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Collegium Pharmaceutical Inc's intrinsic value.